NASDAQ · ERASHealthcarePharmaceuticals

Erasca financials

$14.21+0.57%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$0.00$0.00$0.00$0.00—
Gross profit$0.00$0.00$0.00$0.00—
Gross margin—————
Operating income-$140.9M-$179.6M-$141.5M-$247.4M-$124.9M
Net income-$124.5M-$161.7M-$125.0M-$242.8M-$122.8M
Net margin—————
Diluted EPS$-0.44$-0.69$-0.83$-1.99$-1.85
EBITDA-$137.8M-$175.8M-$137.8M-$244.8M-$124.1M
Operating cash flow-$95.5M-$109.4M-$101.2M-$105.3M-$79.6M
Free cash flow-$95.6M-$109.5M-$103.0M-$119.8M-$90.8M
Diluted shares283.5M233.8M150.2M122.0M66.3M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$73.8M$67.7M$93.1M$284.2M$360.5M
Short-term investments$202.3M$230.6M$219.3M$151.4M$54.0M
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$396.2M$502.5M$395.3M$514.9M$501.4M
Total liabilities$71.0M$79.0M$78.6M$103.1M$44.9M
Shareholders' equity$325.2M$423.5M$316.7M$411.9M$456.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology